Business Context and Reporting Period
Park Ha Biological Technology Co., Ltd. filed a Form 6-K for the month of August 2026, reporting a private placement transaction closed on August 3, 2026. The company is a foreign private issuer headquartered in Wuxi, Jiangsu Province, China.
Key Financial Metrics
This filing details a capital raise rather than operational financial results. Key metrics include:
- Gross Proceeds: Approximately US$1,800,000.
- Shares Issued: 10,000,000 Class A ordinary shares.
- Warrants Issued: Warrants to purchase up to 2,000,000 Class A ordinary shares.
- Purchase Price: US$0.18 per share and accompanying warrant.
- Warrant Exercise Price: US$0.18 per share.
- Warrant Term: Five years from issuance, exercisable immediately.
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity positions.
Material Changes
The primary material change is the increase in share capital and potential dilution resulting from the issuance of 10,000,000 new shares and 2,000,000 warrants. The filing does not provide comparative financial data against prior periods.
Guidance, Outlook, and Risks
Use of Proceeds: The Company intends to use net proceeds for general working capital and corporate purposes.
Regulatory and Transfer Restrictions: The securities were offered in offshore transactions to non-U.S. persons under Regulation S. They are not registered under the Securities Act of 1933 and may not be offered, sold, or transferred in the United States or to U.S. persons absent registration or an exemption.
Warrant Terms: The exercise price and number of warrant shares are fixed and will not be adjusted for share dividends, splits, or recapitalizations.
Investor Verification Checklist
- Verify the final net proceeds after deducting offering expenses.
- Confirm the identity of the non-U.S. purchasers involved in the transaction.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant Agreement (Exhibit 4.1) for specific covenants and indemnification obligations.
- Assess the impact of the new share issuance on existing shareholder dilution.